Retrospective Obseravtional Study Comparing Oral Anticoagulants for Nonvalvular Atrial Fibrillation In Terms Of Comparative Stroke, Bleeding, and Mortality Risks
Latest Information Update: 17 Apr 2019
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke; Thromboembolism
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Apr 2019 Results presented in the Boehringer Ingelheim media release.
- 15 Apr 2019 According to a Boehringer Ingelheim media release, this study was carried out by independent researchers including David J. Graham, MD, MPHm, and funded by US Food and Drug Administration (FDA).
- 13 Feb 2019 New trial record